Drugs / GamCovidVac-M
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04954092 | Jul 2021 → Nov 2022 | COVID-19 | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06068556 | Oct 2023 → Dec 2024 | COVID-19 | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GamCovidVac-M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06068556 ↗ |
| Known as | GamKOVID-Vac M | “Double-blind, placebo-controlled study with open dose selection period for safety assessment, tolerance and immunogenicity of the drug "GamKOVID-Vac M, a combined vector...” NCT04954092 ↗ |
| Modality | Vaccine | “a combined vector vaccine” NCT04954092 ↗ |
| Route | Intramuscular | “The intramuscular vaccine will be administered at vaccination visits # 2 and # 3 (Day 1 and Day 21 ± 2) on an outpatient basis.” NCT04954092 ↗ |